Segunda línea de tratamiento de pacientes con NSCLC PD-L1 positivo: - page 24

Atezolizumab. OAK TRIAL

Barlesi et al, ESMO 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,14,15,16,17,18,19,20,21,22,23 25,26,27,28,29,30,31,32,33